The Treatment of Primary IgA Nephropathy

Dongxu Song, Shengqiang Yu* and Changlin Mei*
Division of Nephrology, Nephrology Institute of PLA, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China

Abstract

IgA Nephropathy (IgAN) is a very common glomerulonephritis worldwide, especially in Asia, which is an important cause of progressive kidney disease with 25–30% of patients developing end-stage renal disease within 20 years of diagnosis. IgA nephropathy can be in different age bracket onset, but mainly in adults. The treatment of primary IgA nephropathy we mentioned in this article is only for adults. The optimal treatment for IgAN remains poorly defined. The current treatment depends on the assessment of proteinuria, blood pressure, estimated Glomerular Filtration Rate (eGFR) and pathological features, including antiproteinuric and antihypertensive therapy, corticosteroids, immunosuppressive agents, fish oil and tonsillectomy. Compounded by the relative lack in IgAN of Randomized Controlled Trials (RCTs), there is no consensus on the use of corticosteroids, immunosuppressive agents, fish oil and tonsillectomy for treatment. The treatment of primary IgA Nephropathy was reviewed from these aspects in this article.

Keywords: Nephropathy; Glomerular filtration rate; Immunoglobulin

Introduction

IgA nephropathy is a chronic form of glomerulonephritis characterized by deposits of predominantly immunoglobulin A in the glomeruli. Deposits of complement C3 and immunoglobulin G are also often found. This disease can be divided into two types, the primary IgA nephropathy which is caused by kidney itself, and secondary IgA nephropathy, that the glomerular immunoglobulin A deposits are associated with Henoch-Schönlein purpura, HIV infection, negative serum spinal arthritis, tumor, etc. The classic presentation (in 40-50% of the cases) is episodic hematuria which usually starts within a day or two of a non-specific upper respiratory tract infection as opposed to post-streptococcal glomerulonephritis which occurs some time (weeks) after initial infection. Loin pain can also occur. Renal function usually remains normal, though rarely, acute renal failure may occur in younger adults. Nephrotic syndrome occurs in around 5% of cases. Acute renal failure may result from acute tubular necrosis as a consequence of macroscopic hematuria or superimposed crescentic nephritis and is seen during the course of the disease in 5% of cases. 5% of the patients who probably had longstanding undetected microscopic hematuria and/or proteinuria developed to chronic kidney disease [1,2]. Its diagnosis is based on histopathologic and immunofluorescence studies on renal biopsy. ACEI or ARB drugs, antithrombotic agents, steroid, immunosuppressive agents, fish oil and tonsillectomy are the present therapy strategies for primary IgA nephropathy in adults. Until now, there is insufficient evidence for the additional use of some of the above drugs. In this review, we focus on the treatment in primary IgA nephropathy.

ACEI or ARB Drugs

The most common mechanism of deterioration of renal function is caused by glomerular hypertension and hyperfiltration that arise from a reduction in the remaining normal, uninjured nephron by glomerular obsolescence [2]. Proteinuria and hypertension are two of the strongest predictors of outcome in IgAN, which can be treated by renin–angiotensin–aldosterone system inhibitors (RASIs), such as Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) to suppress glomerular hypertension and hyper filtration (Table 1). The KDIGO 2012 recommends long term ACEI or ARB treatment when proteinuria is >0.5 g/d [3]. The dosage of the drug depends on the blood pressure and proteinuria level. An RCT that lasted 6 years included 207 patients suggested that high-dose ARB therapy is possibly of recovery of renal function on long-term high-dose therapy compared with normal dose ARB and ACEI [4]. Another retrospective study in Japan suggested that ACEIs or ARBs were effective for long-term renal survival of advanced IgAN (eGFR< 60 ml/min), although proteinuria and blood pressure did not decrease [5]. But a recent RCT which used ramipril 2.5 mg daily to treat IgAN patients with proteinuria <0.5 g/d followed for 5 years indicated that compared with no treatment, ACEI therapy did not offer any benefit in these patients [6]. Commonly, no recommendation on the use of the combination therapy ACEI plus ARB is possible in IgAN patients. But a meta-analysis included 6 RCTs showed that combination therapy ACEI plus ARB may provide more benefits to IgAN patients for reducing daily proteinuria [7]. In our opinion, these RCTs did not have a large sample and a long follow-up, the risk of hyperkalemia also should be put into grave concern, so the long-term effects of these agents on renal outcomes, and safety needed to be established.

Corticosteroids

The other important mechanism of deterioration of renal function is caused by which aberrantly glycosylated serum IgA1 causes mesangial IgA deposition and inflammatory changes, such as crescent formation and endothelial hyper cellularity in the glomeruli [2]. This can be treated by steroid therapy to suppress inflammatory changes in the glomeruli and interstitium [8] (Table 2). IgAN patients with persistent proteinuria ≥ 1g/d, despite optimized supportive care, should be given a 6-month course of corticosteroids if GFR is above 50 ml/min. Compared with support therapy alone, steroid therapy for six months provided additional benefits in preventing the progression of renal disease [9-11]. The steroid therapy consists of two strategies, pulse plus oral steroids and oral steroids only. The effect of two strategies appears to be equal. The risk for adverse events increases in IgAN patients with steroid therapy, so the safety needs high-quality trial with a large sample size [12]. Strictly alternating or low-dose corticosteroid therapy is ineffective [13-15].
Methylprednisolone: MP; a 50% increase in baseline serum creatinine level.

Patients on high-dose ARB had significantly higher eGFR than ACEI/ARB alone for reducing daily proteinuria (p<0.0005).

Steroid pulse therapy significantly decreased the rate of eGFR decline in patients in the combination treatment group. The combined treatment reduced 24-h proteinuria more than ramipril alone during the first 2 years.

Treated with 500 mg intravenous MP every 2 weeks for 6 months. All patients had been maintained on an ACEI or ARB.

73% had improvements in the monthly decline of eGFR. The rate of eGFR decline in the before treatment period differed significantly from that in the after treatment period.

**Methylprednisolone: MP; * A 50% increase in baseline serum creatinine level. **Doubling of baseline serum creatinine or end-stage kidney disease.

### Table 1: The studies of IgAN treatment with RASIs.

<table>
<thead>
<tr>
<th>Published time</th>
<th>Research type</th>
<th>Research object</th>
<th>Follow-up time</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1999 [9]</td>
<td>Prospective cohort study</td>
<td>86 IgAN; urine protein 1.0 – 3.5 g/d, SCR ≤133 μmol/L (1.5 mg/dL)</td>
<td>5 years</td>
<td>Supportive therapy alone or steroid treatment (IV MP 1 gX3 d at the beginning of months 1, 3, and 5, plus oral prednisone 0.5 mg/kg on alternate days for 6 months)</td>
<td>20.9% in the steroid group and 32.6% in the control group reached the primary endpoint* (p=0.048)</td>
</tr>
<tr>
<td>2006 [14]</td>
<td>Retrospective cohort study</td>
<td>702 IgAN patients</td>
<td>5 years</td>
<td>Oral steroids (n=194), MP pulse therapy followed by oral prednisone (n=34), 474 patients with no steroid</td>
<td>24.1% in the ACEI group and 3% in the combination group reached the primary end point*. Urine protein excretion significantly decreased in patients in the combination group</td>
</tr>
<tr>
<td>2009 [10]</td>
<td>Prospective cohort study</td>
<td>83 IgAN patients with proteinuria of 1 to 5 g/d.</td>
<td>4 years</td>
<td>Cilazapril alone (ACEI group; n=30) or steroid plus cilazapril (combination group; n=33)</td>
<td>26.5% in the monotherapy group reached the primary outcome** compared with 4.2% in the combination therapy group. The combined treatment reduced 24-h proteinuria more than ramipril alone during the first 2 years</td>
</tr>
<tr>
<td>2009 [11]</td>
<td>Prospective cohort study</td>
<td>97 IgAN patients with moderate histologic lesions, proteinuria ≥1.0 g/d; GFR&lt;60 ml/min</td>
<td>8 years</td>
<td>6-month course of oral prednisone plus ramipril (combination therapy group) or ramipril alone (monotherapy group)</td>
<td>73% had improvements in the monthly decline of eGFR. The rate of eGFR decline in the before treatment period differed significantly from that in the after treatment period</td>
</tr>
<tr>
<td>2012 [15]</td>
<td>Observational study</td>
<td>22 active IgAN (median histological Grade 3) patients with CKD Stage 3-5; median eGFR 34.05 ml/min</td>
<td>Not known</td>
<td>Treated with 500 mg intravenous MP every 2 weeks for 6 months. All patients had been maintained on an ACEI or ARB</td>
<td>73% had improvements in the monthly decline of eGFR. The rate of eGFR decline in the before treatment period differed significantly from that in the after treatment period</td>
</tr>
</tbody>
</table>

### Table 2: The studies of IgAN treatment with corticosteroids.

### Immunosuppressive Agents

The treatment of primary IgA nephropathy also includes a series of immunosuppressant therapy (Table 3). A clinical trial which included 40 Chinese IgAN patients with a follow-up of 6 years showed that MMF treatment may result in transient and partial remission of proteinuria in the short-term and renoprotection in the long-term [16]. But these promising results should be confirmed in larger RCT clinical trials.

**Kidney Diseases & Treatment**

**Volume 3 • Issue 3 • 1000144**
to the patients with a GFR level of more than 50 ml/min, combined
whether they have decreased GFR or hypertension. During follow-up,
receive a follow-up at least for 10 years.

little or no proteinuria (<0.5 g/d), no specific treatment is required if
of each clinical presentation encountered in IgAN.

possible in IgAN patients.
[30]. However, no recommendation on the use of tonsillectomy is
steroid-pulse (TSP) therapy increased the probability of CR compared
patients [28,29]. A retrospective study showed that tonsillectomy and
remission and delayed renal deterioration even in non-steroid-treated
with a favorable renal outcome of IgA nephropathy in terms of clinical
Further large scale trials are needed to shed more light on this issue.

oil therapy for proteinuria and renal function in IgA nephropathy [27].
suggested that there were insufficient data to confirm the efficacy of fish
contrast, a meta-analysis which included five RCTs (239 patients)
iGn patients. This trial indicated that fish oil therapy was a safe
based on the Japanese Society of Nephrology classification system for
IgAN patients with an
creatinine ≤ 2.0 mg/dl
207 IgAN patients with
creatinine ≥ 2.0 mg/dl
and proteinuria ≥ 1.0 g/d
median follow-
up of 4.9 years
A 3-day pulse of MP in months 1, 3, and 5 in
addition to both oral prednisone 0.5 mg/kg every
other day and azathioprine 1.5 mg/kg per day for
6 months (n=101). steroids alone on the same
schedule (n=105)
Low-dose azathioprine to corticosteroids for 6
months does not provide additional benefit to
patients with IgAN and may increase the risk
for adverse events

2010 [21]
Prospective
cohort study

2010 [16]
Prospective
cohort study

2011 [19]
Prospective
cohort study

2011 [22]
Prospective
cohort study

2012 [23]
Prospective
cohort study

2 years

6 years

Not known

1 year

Not known

1 g/d

Not known

1 g/d

40 Chinese patients with
IgA nephritis

22 IgAN patients with
eGFR ≥ 30 ml/min, urine
protein ≥ 1 g/d, BP <
130/80 mmHg

23 IgAN patients with a
GFR within 30–60 ml/
min and/or proteinuria
>1 g/d

14 refractory IgAN
patients

All patients were maintained on ARB medication and half were randomized to receive MMF for 6 m

Methylprednisolone alone or MP combination with azathioprine for 12 months. All the patients were treated with RASIs and PFA for at least 6 m

Low-dose sirolimus plus enalapril and atorvastatin (SRL group, n=14) or enalapril plus atorvastatin (CONTROL group, n=9)

Tacrolimus (0.05-0.1 mg/kg/d) and prednisone (0.5 mg/kg/d) for at least 6 m

9 patients showed complete or partial remission and 7 patients achieved remission within 1 m

1.5% in the MMF group and 5% in the control group reached the composite end point*. Urinary protein excretion and the albumin-
to-creatinine ratio were lower with MMF treatment during the first 24 m

Two groups seem to be effective in reducing the severity of proteinuria and stabilizing renal function.

Primary end point** improved significantly in the SRL group. 12 months. Proteinuria decreased similarly in both study groups

* Serum creatinine doubling or end-stage renal disease.
** Variation of hematuria, proteinuria and blood pressure.

Table 3: The studies of IgAN treatment with immunosuppressive agents.

Published time Research type Research object Follow-up time Treatment Outcome
2005 [17] Prospective cohort study 32 North American IgAN patients with an eGFR < 60 ml/min 1 year of MMF, titrated up to a dose of 1000 mg bid, or placebo. All patients received RASIs medication
29.4% in the MMF group and 13.3% in the control group reached a 50% increase in Scr (P<0.4). 17.6% in the MMF group and 13.3% in the control group had a 50% reduction in 24 h proteinuria

2010 [21] Prospective cohort study 207 IgAN patients with creatinine ≤ 2.0 mg/dl and proteinuria ≥ 1.0 g/d median follow-up of 4.9 years

A 3-day pulse of MP in months 1, 3, and 5 in addition to both oral prednisone 0.5 mg/kg every other day and azathioprine 1.5 mg/kg per day for 6 months (n=101). steroids alone on the same schedule (n=105)

Low-dose azathioprine to corticosteroids for 6 months does not provide additional benefit to patients with IgAN and may increase the risk for adverse events

2010 [16] Prospective cohort study 40 Chinese patients with IgA nephritis 6 years

All patients were maintained on ARB medication and half were randomized to receive MMF for 6 m

1.5% in the MMF group and 5% in the control group reached the composite end point*. Urinary protein excretion and the albumin-to-creatinine ratio were lower with MMF treatment during the first 24 m

2011 [19] Prospective cohort study 22 IgAN patients with eGFR ≥ 30 ml/min, urine protein ≥ 1 g/d, BP < 130/80 mmHg Not known

Methylprednisolone alone or MP combination with azathioprine for 12 months. All the patients were treated with RASIs and PFA for at least 6 m

Two groups seem to be effective in reducing the severity of proteinuria and stabilizing renal function.

2011 [22] Prospective cohort study 23 IgAN patients with a GFR within 30–60 ml/min and/or proteinuria >1 g/d 1 year

Low-dose sirolimus plus enalapril and atorvastatin (SRL group, n=14) or enalapril plus atorvastatin (CONTROL group, n=9)

Primary end point** improved significantly in the SRL group. 12 months. Proteinuria decreased similarly in both study groups

2012 [23] Prospective cohort study 14 refractory IgAN patients Not known

Tacrolimus (0.05-0.1 mg/kg/d) and prednisone (0.5 mg/kg/d) for at least 6 m

9 patients showed complete or partial remission and 7 patients achieved remission within 1 m

A small Japanese clinical trial in the IgAN patients showed a significant improvement in estimated creatinine clearance in fish oil group (1.8 g/d for 12 months), but not in the control group. No side effects were noted. All the patients were treated by the assessment based on the Japanese Society of Nephrology classification system for IgA nephropathy. This trial indicated that fish oil therapy was a safe and worthwhile supplement to the drugs used to treat IgAN [26]. In contrast, a meta-analysis which included five RCTs (239 patients) suggested that there were insufficient data to confirm the efficacy of fish oil therapy for proteinuria and renal function in IgA nephropathy [27]. Further large scale trials are needed to shed more light on this issue.

Several studies in Japan reported that Tonsillectomy was associated with a favorable renal outcome of IgA nephropathy in terms of clinical remission and delayed renal deterioration even in non-steroid-treated patients [28,29]. A retrospective study showed that tonsillectomy and steroid-pulse (TSP) therapy increased the probability of CR compared with tonsillectomy alone in IgAN patients with urinary abnormalities [30]. However, no recommendation on the use of tonsillectomy is possible in IgAN patients.

** Variation of hematuria, proteinuria and blood pressure.

Therapeutics Strategy

Here we will review the available treatments from the perspective of each clinical presentation encountered in IgAN.

For the IgAN patients with isolated microscopic hematuria and little or no proteinuria (<0.5 g/d), no specific treatment is required if they have normal GFR and no hypertension, although patients should receive a follow-up at least for 10 years.

For the IgAN patients with proteinuria more than 0.5-1 g/d, supportive treatment for 3-6 months should be received no matter whether they have decreased GFR or hypertension. During follow-up, to the patients with a GFR level of more than 50 ml/min, combined with corticosteroid therapy may be considered if the level of proteinuria persists for more than 1 g/d.

Acute kidney injury often occurs with macroscopic hematuria. Renal biopsy should be given because that will distinguish acute kidney injury between acute tubular necrosis and crescentic IgAN. Acute tubular necrosis would be self-limiting with continuing supportive treatment while the crescentic IgAN needs high-dose corticosteroids and cyclophosphamide combined with support treatment, and in some cases, using plasma exchange.

For the patients with nephrotic syndrome, IgAN with minimal change nephropathy should be treated similar to the minimal-change disease. There are few RCTs about the treatment strategies of other types of IgAN with nephrotic syndrome. But one point is important, that is the indiscriminate use of corticosteroid should be discouraged.

Conclusions

There still remain many problems in treatment of IgAN to resolve, such as the efficacy and safety of corticosteroid, the use of immunosuppressive agents, the treatment strategies in patients with nephrotic syndrome and so on. Now the ongoing TESTING Study, sponsored by The George Institute and collaborated by Peking University First Hospital, will evaluate the long-term efficacy and safety of oral methylprednisolone alone or MP combination with azathioprine for 12 months. All the patients were treated with RASIs and PFA for at least 6 m

[31]. There still remain many problems in treatment of IgAN to
resolve, such as the efficacy and safety of corticosteroid, the use of
immunosuppressive agents, the treatment strategies in patients with
nephrotic syndrome and so on. Now the ongoing TESTING Study,
sponsored by The George Institute and collaborated by Peking
University First Hospital, will evaluate the long-term efficacy and
safety of oral methylprednisolone alone or MP combination with
azathioprine for 12 months. All the patients were treated with
RASIs and PFA for at least 6 m

References


